丙型肝炎

American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. May 2018 [internet publication].

• 全文

Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637-648.

• 全文
• 摘要

Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute clinical practice update - expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 2017;152:1578-1587.

• 全文
• 摘要

1.  Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015;44:717-734.

• 摘要

2.  Dultz G, Zeuzem S. Hepatitis C virus: a European perspective. Gastroenterol Clin North Am. 2015;44:807-824.

• 摘要

3.  Dan YY, Lim SG. Hepatitis C: an Eastern perspective. Gastroenterol Clin North Am. 2015;44:793-805.

• 摘要

4.  Hoofnagle JH. Hepatitis C: the clinical spectrum of disease. Hepatology. 1997;26(suppl 1):15s-20s.

• 摘要

5.  Alter MJ, Margolis HS, Krawczynski K, et al.The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. N Engl J Med. 1992;327:1899-1905.

• 摘要

6.  World Health Organization. Global hepatitis report, 2017. April 2017. http://apps.who.int (last accessed 27 September 2017).

• 全文

7.  Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87.

• 全文
• 摘要

8.  Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(suppl):S45-S57.

• 全文
• 摘要

9.  World Health Organization. Hepatitis C - global prevalence (update). Wkly Epidemiol Rec. 1999;74:425-427.

• 全文
• 摘要

10.  Public Health England. Hepatitis C in the UK: 2017 report. London: PHE publications; 2017.

• 全文

11.  Nouroza F, Shaheena S, Mujtaba G, et al. An overview on hepatitis C virus genotypes and its control. Egypt J Med Hum Gen. 2015;16:291-298.

• 全文

12.  Centers for Disease Control and Prevention. Surveillance for viral hepatitis - United States, 2014: hepatitis C. November 2016. http://www.cdc.gov/ (last accessed 27 September 2017).

• 全文

13.  Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.

• 摘要

14.  Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis. 2000;20:1-16.

• 摘要

15.  Mahowald MK, Larney S, Zaller ND, et al. Characterizing the burden of hepatitis C infection among entrants to Pennsylvania state prisons, 2004 to 2012. J Correct Health Care. 2016;22:41-45.

• 全文
• 摘要

16.  Ly KN, Jiles RB, Teshale EH, et al. Hepatitis C virus infection among reproductive-aged women and children in the United States, 2006 to 2014. Ann Intern Med. 2017;166:775-782.

• 摘要

17.  Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2010;138:513-521.

• 摘要

18.  Mahajan R, Xing J, Liu SJ, et al. Mortality among persons in care with hepatitis C virus infection: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2010. Clin Infect Dis. 2014;58:1055-1061.

• 全文
• 摘要

19.  Alter MJ. Prevention of spread of hepatitis C. Hepatology. 2002;36(5 Suppl 1):S93-S98.

• 摘要

20.  Garcia-Tejedor A, Maiques-Montesinos V, Diago-Almela VJ, et al. Risk factors for vertical transmission of hepatitis C virus: a single center experience with 710 HCV-infected mothers. Eur J Obstet Gynecol Reprod Biol. 2015;194:173-177.

• 摘要

21.  Indolfi G, Nesi A, Resti M. Intrafamilial transmission of hepatitis C virus. J Med Virol. 2013;85:608-614.

• 摘要

22.  Gerlach JT, Diepolder HM, Zachoval R. Acute hepatitis C: high rate of both spontaneous and treatment -induced viral clearance. Gastroenterology. 2003;125:80-88.

• 摘要

23.  Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12:96-102.

• 摘要

24.  Smith JA, Aberle JH, Fleming VM, et al. Dynamic coinfection with multiple viral subtypes in acute hepatitis C. J Infect Dis. 2010;202:1770-1779.

• 全文
• 摘要

25.  World Health Organization. WHO best practices for injections and related procedures toolkit. March 2010. http://apps.who.int/ (last accessed 27 September 2017).

• 全文
• 摘要

26.  Garfein RS, Vlahov D, Galai N, et al. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-661.

• 全文
• 摘要

27.  Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Database Syst Rev. 2017 Sep 18;9:CD012021.

• 全文
• 摘要

28.  Pomper GJ, Wu Y, Snyder EL. Risks of transfusion-transmitted infections: 2003. Curr Opin Hematol. 2003;10:412-418.

• 摘要

29.  Centers for Disease Control and Prevention. CDC announces first ever national hepatitis testing day and proposes that all baby boomers be tested once for hepatitis C. May 2012. http://www.cdc.gov/ (last accessed 27 September 2017).

• 全文

30.  Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798-801.

• 摘要

31.  Pearlman BL. Hepatitis C virus infection in African Americans. Clin Infect Dis. 2006;42:82-91.

• 摘要

32.  Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18:52-61.

• 摘要

33.  Puro V, Petrosillo N, Ippolito G. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control. 1995;23:273-277.

• 摘要

34.  Jafari S, Copes R, Baharlou S, et al. Tattooing and the risk of transmission of hepatitis C: a systematic review and meta-analysis. Int J Infect Dis. 2010;14:928-940.

• 摘要

35.  Stroffolini T, Lorenzoni U, Menniti-Ippolito F, et al. Hepatitis C virus infection in spouses: sexual transmission or common exposure to the same risk factors? Am J Gastroenterol. 2001;96:3138-3141.

• 摘要

36.  Terrault NA, Dodge JL, Murphy EL, et al. Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology. 2013;57:881-889.

• 全文
• 摘要

37.  Yeung LT, King SM, Roberts EA. Mother-to-infant transmission of hepatitis C virus. Hepatology. 2001;34:223-229.

• 摘要

38.  Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3 Suppl 1):21S-28S.

• 摘要

39.  Hagan H, Des Jarlais DC, Friedman SR, et al. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma Syringe Exchange Program. Am J Public Health. 1995;85:1531-1537.

• 全文
• 摘要

40.  Villano SA, Vlahov D, Nelson KE, et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology. 1999;29:908-914.

• 摘要

41.  Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17-35.

• 摘要

42.  National Institutes of Health. National Institutes of Health consensus development conference statement: management of hepatitis C: 2002 - June 10-12, 2002. Hepatology. 2002;36(suppl 1):S3-S20.

• 摘要

43.  Hézode C, Zafrani ES, Roudot-Thoraval F, et al. Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C. Gastroenterology. 2008;134:432-439.

• 全文
• 摘要

44.  Ishida JH, Peters MG, Jin C, et al. Influence of cannabis use on severity of hepatitis C disease. Clin Gastroenterol Hepatol. 2008;6:69-75.

• 全文
• 摘要

45.  American Association for the Study of Liver Diseases; Infectious Diseases Society of America. HCV guidance: recommendations for testing, managing, and treating hepatitis C. May 2018 [internet publication].

• 全文

46.  Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection. JAMA. 2007;297:724-732.

• 摘要

47.  Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol. 2007;102:2589-2600.

• 摘要

48.  Calvaruso V, Cammà C, Di Marco V, et al. Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy. J Viral Hepat. 2010;17:469-474.

• 摘要

49.  Centers for Disease Control and Prevention. Hepatitis C, acute: 2016 case definition. https://wwwn.cdc.gov/ (last accessed 27 September 2017).

• 全文

50.  Centers for Disease Control and Prevention. Hepatitis C, chronic: 2016 case definition. https://wwwn.cdc.gov/ (last accessed 27 September 2017).

• 全文

51.  Public Health England. Public Health England encourages hepatitis C testing. 28 July 2017. https://www.gov.uk/ (last accessed 26 September 2017).

• 全文

52.  Centers for Disease Control and Prevention. Screening for hepatitis during the domestic medical examination. March 2014. http://www.cdc.gov/ (last accessed 27 September 2017).

• 全文

53.  Moyer VA; US Preventive Services Task Force. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159:349-357.

• 全文
• 摘要

54.  Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in US primary care settings. Ann Intern Med. 2012;156:263-270.

• 摘要

55.  McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55:1344-1355.

• 摘要

56.  Coffin PO, Scott JD, Golden MR, et al. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis. 2012;54:1259-1271.

• 摘要

57.  Jemal A, Fedewa SA. Recent hepatitis C virus testing patterns among baby boomers. Am J Prev Med. 2017;53:e31-e33.

• 摘要

58.  Chappell CA, Hillier SL, Crowe D, et al. Hepatitis C virus screening among children exposed during pregnancy. Pediatrics. 2018 May 2. pii: e20173273.

• 摘要

59.  Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017 Aug 14 [epub ahead of print].

• 全文
• 摘要

60.  Chiu WC, Su YP, Su KP, et al. Recurrence of depressive disorders after interferon-induced depression. Transl Psychiatry. 2017;7:e1026.

• 全文
• 摘要

61.  Jakobsen JC, Nielsen EE, Feinberg J, et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev. 2017;(9):CD012143.

• 全文
• 摘要

62.  Powderly WG, Naggie S, Kim AY, et al. IDSA/AASLD response to Cochrane review on direct-acting antivirals for hepatitis C. Clin Infecti Dis. 17 July 2017. https://academic.oup.com/cid/ (last accessed 26 September 2017).

• 全文

63.  European Association for the Study of the Liver. Response to the Cochrane systematic review on DAA-based treatment of chronic hepatitis C. June 2017. http://www.journal-of-hepatology.eu/content/pressreleases (last accessed 27 September 2017).

• 全文

64.  Jakobsen JC, Nielsen EE, Koretz RL, et al. Do direct acting antivirals cure chronic hepatitis C? BMJ. 2018 May 10;361:k1382.

• 全文
• 摘要

65.  US Food and Drug Administration. FDA drug safety communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. October 2016. https://www.fda.gov/ (last accessed 27 September 2017).

• 全文

66.  European Medicines Agency. PRAC warns of risk of hepatitis B re-activation with direct-acting antivirals for hepatitis C. December 2016. http://www.ema.europa.eu/ (last accessed 27 September 2017).

• 全文

67.  Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, et al. Oral direct-acting agent therapy for hepatitis C virus infection: a systematic review. Ann Intern Med. 2017;166:637-648.

• 全文
• 摘要

68.  Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211-221.

• 全文
• 摘要

69.  Friborg J, Zhou N, Han Z, et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther. 2015;4:137-144.

• 全文
• 摘要

70.  van der Ree MH, de Vree JM, Stelma F, et al. Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial. Lancet. 2017;389:709-717.

• 摘要

71.  Fattovich G, Guistina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.

• 摘要

72.  Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology. 1998;28:1687-1695.

• 摘要

73.  Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis: a study of 200 patients. J Hepatol. 2004;40:823-830.

• 摘要

74.  Jacobson IM, Lim JK, Fried MW. American Gastroenterological Association Institute clinical practice update - expert review: care of patients who have achieved a sustained virologic response after antiviral therapy for chronic hepatitis C infection. Gastroenterology. 2017;152:1578-1587.

• 全文
• 摘要

75.  Bruno S, Zuin M, Crosignani A, et al. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am J Gastroenterol. 2009;104:1147-1158.

• 摘要

76.  Kanwal F, Kramer JR, Ilyas J, et al. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of US Veterans with HCV. Hepatology. 2014;60:98-105.

• 摘要

77.  Innes H, McAuley A, Alavi M, et al. The contribution of health risk behaviours to excess mortality in American adults with chronic hepatitis C: A population cohort-study. Hepatology. 2017 Aug 4 [epub ahead of print].

• 全文
• 摘要

78.  Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018 Jan 19. pii: S2468-1253(18)30002-5.

• 摘要

79.  Ferri C, Zignego AL, Pileri SA. Cryoglobulins. J Clin Pathol. 2002;55:4-13.

• 摘要

80.  Montero N, Favà A, Rodriguez E, et al. Treatment for hepatitis C virus-associated mixed cryoglobulinaemia. Cochrane Database Syst Rev. 2018 May 7;5:CD011403.

• 全文
• 摘要

81.  Johnson RJ, Gretch DR, Yamabe H, et al. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med. 1993;328:465-470.

• 全文
• 摘要

82.  Wilson SE, Lee WM, Murakami C, et al. Mooren-type hepatitis C virus-associated corneal ulceration. Ophthalmology. 1994;101:736-745.

• 摘要

83.  Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology. 1999;29:1311-1316.

• 摘要

84.  Colombo M. Hepatitis C virus and hepatocellular carcinoma. Semin Liver Dis. 1999;19:263-269.

• 摘要

85.  El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.

• 摘要

86.  Molina-Cuadrado E, Mateo-Carrrasco H, Collado A, et al. Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents. Eur J Hosp Pharm. 2017 Jun 21 [Epub ahead of print].

• 全文

87.  Pessione F, Degos F, Marcellin P, et al. Effect of alcohol consumption on serum hepatitis C RNA and histological lesions in chronic HCV. Hepatology. 1998;27:1717-1722.

• 摘要

88.  Terrault NA. Sexual activity as a risk factor for HCV infection. Hepatology. 2002;36(5 Suppl 1):S99-S105.

• 摘要

89.  Centers for Disease Control. Recommendations for prevention and control of HCV and HCV-related chronic disease. MMWR Recomm Rep. 1998:47:1-39.

• 全文

90.  Tohme RA, Holmberg SD. Is sexual contact a major mode of hepatitis C virus transmission? Hepatology. 2010;52:1497-1505.

• 摘要